Mounjaro

Mounjaro is proven to lower A1C in adults with type 2 diabetes*orld!

*Along with diet and exercise.

What is Mounjaro?

Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.

It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.

Image of a down arrow reading most people reached an a1c under 7%

*In studies with or without diabetes medications, 75% to 90% of people taking Mounjaro reached an A1C of less than 7%, with an average starting A1C of 7.9% to 8.6% across the 5-mg, 10-mg, and 15-mg doses.
Study results were measured at 40 and 52 weeks.

Select Safety Information

Warning

Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats, Mounjaro and medicines that work like Mounjaro caused thyroid tumors, including thyroid cancer. It is not known if Mounjaro will cause thyroid tumors, or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not take Mounjaro if you or any of your family have ever had MTC or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

People taking Mounjaro also lost up to 25 pounds

Mounjaro is not a weight loss drug.

Individual results may vary. In studies with or without other diabetes medications, weight loss in adults ranged from 12 lb (5 mg) to 25 lb (15 mg).

Select Safety Information

Do not use Mounjaro if you or any of your family have ever had a type of thyroid cancer called MTC or if you have an endocrine system condition called MEN 2, or if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Mounjaro.

Leave a Reply

Your email address will not be published. Required fields are marked *